Applied Filters
10x Genomics 'overjoyed' to win UPC preliminary injunction
Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu.
EPO launches Unitary Patent dashboard revealing daily take-up figures
Interactive statistics chart shows more than 5,000 requests for unitary effect | Data can be filtered by country, language and technology sector.
Compugen’s anti-PVRIG patent upheld by the EPO
Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
UPC: Milan confirmed as third seat but Munich lands chemistry, minus SEPs
UPC Administrative Committee 'voted unanimously' to approve Milan says Italian politician | Court will hear patent cases related to “pharmaceutical, phytosanitary, agri-food and fashion” | Chemistry and metallurgy moving to Munich, excluding SEPs.
UK appoints first female Lord Chief Justice in 755 years
Dame Sue Carr takes over from Lord Burnett of Maldon, assuming responsibilities in October.
European Commission proposes ‘single market’ for meds
Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.
Cipla loses fightback over diarrhoea antibiotic
Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.
EPO Enlarged Board of Appeal issues G 2/21 decision
Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Oxford University startup ordered to pay royalties
‘Rare’ case included ‘campaigning element’ says judge | Ex-student sought clarification on royalties from university | 651-paragraph ruling required Oxford Uni to justify its IP policies.
Amgen seals $28m deal for biotech
Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.
